Back to Interventions

Substance / Medication

Phenylpropanolamine

SNOMED 387464001 UMLS C0031495

Overview

Active Ingredient

phenylpropanolamine

RxNorm CUI

8175

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

LOINC 2093-3

secondary

LOINC 4549-2

secondary

LOINC 2571-8

secondary

Clinical Trials

426 trials linked to this intervention

426

Total Trials

122

Recruiting

109

With Results

Recent Trials

Diabetes and Heart Disease Risk in Blacks

NCT00001853Recruiting2000 enrolled

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

NCT00009555Phase 4Completed86 enrolled

Pediatric Hypothalamic Obesity

NCT00076362Phase 4Completed60 enrolled

The Safety and Effectiveness of Low and High Carbohydrate Diets

NCT00079547Phase 4Completed307 enrolled

Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity

NCT00134303Phase 4Completed65 enrolled

View all 426 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature.

Salerno S M, Jackson J L, Berbano E P · J Hum Hypertens · 2005

PMID: 15944721Meta-Analysis

Retrograde ejaculation occurs in the dog, but can be prevented by pre-treatment with phenylpropanolamine: a urodynamic study.

Beaufays F, Onclin K, Verstegen J · Theriogenology · 2008

PMID: 18675452RCT

Phenylpropanolamine's decongestive effect on the nasalmucosa of pregnant women with nasal stuffiness.

Toll Karin, Graf Peter · Rhinology · 2006

PMID: 17216745RCT

Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.

Azzaro Albert J, VanDenBerg Chad M, Ziemniak John et al. · J Clin Pharmacol · 2007

PMID: 17554106Trial

Urodynamic and morphologic changes in the lower portion of the urogenital tract after administration of estriol alone and in combination with phenylpropanolamine in sexually intact and spayed female dogs.

Hamaide Annick J, Grand Jean-Guillaume, Farnir Frédéric et al. · Am J Vet Res · 2006

PMID: 16649928Trial

A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women.

Cooper Theodore V, Klesges Robert C, Debon Margaret W et al. · Addict Behav · 2005

PMID: 15561449Trial

Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.

Chester N, Reilly T, Mottram D R · Int J Sports Med · 2003

PMID: 12582945Trial

Evaluation of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch.

Scott L, Leddy M, Bernay F et al. · J Small Anim Pract · 2002

PMID: 12463265Trial

Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment.

Borovicka Mary C, Fuller Matthew A, Konicki P Eric et al. · J Clin Psychiatry · 2002

PMID: 12000209Trial

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

Hendershot P E, Antal E J, Welshman I R et al. · J Clin Pharmacol · 2001

PMID: 11361053Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Obesity Medicine (Family Medicine) Physician

Family Medicine — Obesity Medicine

NUCC 207QB0002X

Obesity Medicine (Internal Medicine) Physician

Internal Medicine — Obesity Medicine

NUCC 207RB0002X

Endocrinology, Diabetes & Metabolism Physician

Internal Medicine — Endocrinology, Diabetes & Metabolism

NUCC 207RE0101X

Find a Provider

Health Goals

Goals connected through associated conditions

Manage Weight and Body Composition Optimize Metabolic Function

Quick Facts

Type: Substance / Medication
Fully Specified Name: Phenylpropanolamine (substance)
SNOMED CT: 387464001
UMLS CUI: C0031495
RxNorm CUI: 8175

Clinical Data

This intervention maps to 11 entities in the Ltrl knowledge graph.

3

Conditions

3

Biomarkers

3

Specialists

0

Symptoms

426

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Phenylpropanolamine: Uses, Evidence & Side Effects | Ltrl